Nitric oxide is a chemical compound in gas form that is sometimes used to treat infants with severe breathing problems associated with narrow blood vessels in the lungs. It works by relaxing smooth muscle to widen (dilate) blood vessels, especially in the lungs. Nitric oxide is usually used together with a breathing machine (ventilator).
Inhaled nitric oxide (iNO) is recognized as a potent and selective pulmonary vasodilator that does not decrease systemic vascular tone. The therapeutic application of iNO in human was first described in 1990s. INO therapy was effective to improve oxygenation in infants with persistent pulmonary hypertension of the newborn (PPHN). Owing to its selective pulmonary vasodilator effects, iNO therapy is an important treatment for term newborns with hypoxemic respiratory failure due to PPHN. The Food and Drug Administration of the United States of America first approved iNO in 1999 for use as a medical gas to treat hypoxic respiratory failure associated with clinical or echocardiographic evidence of pulmonary hypertension in term and late preterm neonates. Thereafter, iNO therapy is clinically applied to treat PPHN in term and late preterm neonates without consensus.
According to our (Global Info Research) latest study, the global Inhaled Nitric Oxide market size was valued at USD 1115.4 million in 2022 and is forecast to a readjusted size of USD 1904.5 million by 2029 with a CAGR of 7.9% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Mallinckrodt monopolizes the global Inhaled Nitric Oxide market, holding a share about 65%.
North America is the largest market, with a share about 77%, followed by Asia-Pacific and Europe, have a share about 20 percent.
In terms of product, 800 ppm is the largest segment, with a share over 50%. And in terms of application, the largest application is Near-term and Pre-term Infants PPHN, followed by Children and Adult ARDS, etc.
Get Free Sample Report @ https://www.globalinforesearch.com/reports/991043/inhaled-nitric-oxide
This report is a detailed and comprehensive analysis for global Inhaled Nitric Oxide market. Both quantitative and qualitative analyses are presented by manufacturers, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Market segment by Type
800 ppm
100 ppm
Others
Market segment by Application
Near-term and Pre-term Infants PPHN
Children and Adult ARDS
Other Diseases
Major players covered
Mallinckrodt
Praxair (Linde plc)
Air Liquide
BOC Healthcare (Linde Group)
About US
Global Info Research is a report publisher, a customer, interest-based suppliers. Is in the best interests of our clients, they determine our every move. At the same time, we have great respect for the views of customers. With the improvement of the quality of our research, we develop custom interdisciplinary and comprehensive solution. For further development, we will do better and better. GlobalInfoResearch will with excellent professional knowledge and experience to carry out all aspects of our business. At the same time, we will thoroughly look for information, to give a more comprehensive development.
Contact US
Global Info Research
E-mail: report@globalinforesearch.com
Tel: +86-17665052062 00852-58197708(HK)
WeChat: 17665052062
Add:FLAT/RM A 9/F SILVERCORP INTERNATIONAL TOWER 707-713 NATHAN ROAD MONGKOK KL HONG KONG
Website: http://www.globalinforesearch.com
No comments:
Post a Comment